138 DOM
ordinary movement as stroboscopic jerkiness, seeing surfaces moving sinu-
ously, and feeling like one was no longer located in one’s body.
Drawbacks.An experiment documented physical sensations that included
warmth, tingling, dizziness, nausea, tremors, rapid heartbeat, impaired move-
ment, coughing, sweating, and lack of hunger. Insomnia has also been re-
ported. In rats DOM can raise body temperature and lower appetite.
Supposedly effects from a single dose can last for three days, but in a group
of 25 volunteers who took substantial doses, only 2 persons experienced effects
lasting past the day of the experiment, and none had any effects on the second
day afterward. Some users who expect the drug to act like LSD have not
realized that DOM effects take longer to develop, and after waiting the
amount of time they would wait for LSD actions to begin, those persons have
taken more DOM in a mistaken belief that the original amount was not
enough. The result can be an overdose emergency. Achieving such an over-
dose apparently takes dedication; one estimate puts DOM’s safety index at
10,000 (meaning a person would have to take 10,000 times the amount of a
standard effective dose in order to be poisoned). Some investigators wonder
if previous use of psychoactive drugs makes people more sensitive to DOM,
thereby making overdose easier.
Abuse factors.Tolerance can develop.
Drug interactions.Not enough scientific information to report.
Cancer.Not enough scientific information to report.
Pregnancy.Not enough scientific information to report.
Additional scientific information may be found in:
Hollister, L.E., M.F. Macnicol, and H.K. Gillespie. “An Hallucinogenic Amphetamine
Analog (DOM) in Man.”Psychopharmacologia14 (1969): 62–73.
Ropero-Miller, J.D., and B.A. Goldberger. “Recreational Drugs: Current Trends in the
90s.”Clinics in Laboratory Medicine18 (1998): 727–46.
Shulgin, A.T., T. Sargent, and C. Naranjo. “4-Bromo-2,5-Dimethoxyphenyliso-
propylamine, a New Centrally Active Amphetamine Analog.”Pharmacology 5
(1971): 103–7.
Snyder, S.H., L.A. Faillace, and H. Weingartner. “DOM (STP), a New Hallucinogenic
Drug, and DOET: Effects in Normal Subjects.”American Journal of Psychiatry 125
(1968): 357–64.
Snyder, S.H., L. Faillace, and L. Hollister. “2,5-Dimethoxy-4-Methyl-Amphetamine
(STP): A New Hallucinogenic Drug.”Science158 (1967): 669–70.
